Allogene Therapeutics ALLO Business Segments — Cema-cel

Similar metrics at other companies

VIRReportable Segment — Clinical costs

$26.13M+26.8%

RXRXReportable Segment — Clinical development

$6.57M-37.8%

RCUSReportable segment — Early-stage development and preclinical programs

$18M-57.1%

CRNXReportable Segment — Expenses Related To Atumelnant

$20.27M+162%

CDNAReportable Segment — Research materials and clinical trials expense

$3.83M+20.7%

AVTXReportable Segment — CMC expenses

$4.13M+108%

Questions, answered.

What is Allogene Therapeutics's business segments — cema-cel?

Allogene Therapeutics (ALLO) reported business segments — cema-cel of $7.67M in Q1 2026.

How has Allogene Therapeutics's business segments — cema-cel changed year-over-year?

Allogene Therapeutics's business segments — cema-cel increased by 23.3% year-over-year, from $6.22M to $7.67M.

What is the long-term trend for Allogene Therapeutics's business segments — cema-cel?

Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — cema-cel has grown at a -26.5% compound annual growth rate (CAGR), from $43.23M to $23.37M.

What does business segments — cema-cel mean?

This metric represents the direct research and development expenditures specifically allocated to the Cema-cel clinical program. It tracks the capital intensity of this lead asset as it progresses through clinical trials. Monitoring these costs helps investors assess the company's investment commitment to its primary therapeutic candidate.